These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24638135)

  • 21. Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models.
    Busche MA; Grienberger C; Keskin AD; Song B; Neumann U; Staufenbiel M; Förstl H; Konnerth A
    Nat Neurosci; 2015 Dec; 18(12):1725-7. PubMed ID: 26551546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Alzheimer's disease: the beginning of a new era.
    Schenk D
    Curr Alzheimer Res; 2006 Jul; 3(3):177. PubMed ID: 16842091
    [No Abstract]   [Full Text] [Related]  

  • 23. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
    Schenk DB; Seubert P; Grundman M; Black R
    Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccines: chasing the dream.
    Schnabel J
    Nature; 2011 Jul; 475(7355):S18-9. PubMed ID: 21760578
    [No Abstract]   [Full Text] [Related]  

  • 25. [Immunotherapy for Alzheimer's disease].
    Falkentoft AC; Hasselbalch SG
    Ugeskr Laeger; 2016 Jan; 178(3):V07150588. PubMed ID: 26815584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapies for Alzheimer's disease.
    Golde TE; Levey AI
    Science; 2023 Dec; 382(6676):1242-1244. PubMed ID: 38096276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.
    Taguchi H; Planque S; Nishiyama Y; Szabo P; Weksler ME; Friedland RP; Paul S
    Autoimmun Rev; 2008 May; 7(5):391-7. PubMed ID: 18486927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Advances in anti-beta antibody treatment of Alzheimer's disease].
    Zhang JH; Liang P
    Zhonghua Bing Li Xue Za Zhi; 2007 Sep; 36(9):633-5. PubMed ID: 18070457
    [No Abstract]   [Full Text] [Related]  

  • 29. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.
    Murakami K
    Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.
    Nitsch RM; Hock C
    Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer's amyloid immunotherapy: quo vadis?
    Gandy S; Heppner FL
    Lancet Neurol; 2005 Aug; 4(8):452-3. PubMed ID: 16033686
    [No Abstract]   [Full Text] [Related]  

  • 32. [The role of beta-amyloid peptide in pathogenesis and immunotherapy of Alzheimer's diseases].
    Yu SN; Liu LY; Liang P
    Zhonghua Bing Li Xue Za Zhi; 2005 Feb; 34(2):113-4. PubMed ID: 15842811
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy.
    Sengupta U; Nilson AN; Kayed R
    EBioMedicine; 2016 Apr; 6():42-49. PubMed ID: 27211547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aβ immunotherapy for Alzheimer's disease: where are we?
    Güell-Bosch J; Montoliu-Gaya L; Esquerda-Canals G; Villegas S
    Neurodegener Dis Manag; 2016 Jun; 6(3):179-81. PubMed ID: 27230296
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunotherapy for Alzheimer disease.
    Gouras GK
    MAbs; 2009; 1(2):112-4. PubMed ID: 20061820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bapineuzumab in Alzheimer's disease: where now?
    Wilcock GK
    Lancet Neurol; 2010 Feb; 9(2):134-6. PubMed ID: 20129159
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunotherapy for Alzheimer disease: the challenge of adverse effects.
    Liu YH; Giunta B; Zhou HD; Tan J; Wang YJ
    Nat Rev Neurol; 2012 Aug; 8(8):465-9. PubMed ID: 22751529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.
    Roher AE; Maarouf CL; Daugs ID; Kokjohn TA; Hunter JM; Sabbagh MN; Beach TG
    J Alzheimers Dis; 2011; 24(2):315-25. PubMed ID: 21263194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Development of therapies of Alzheimer's disease].
    Shoji M
    Nihon Ronen Igakkai Zasshi; 2003 Sep; 40(5):473-5. PubMed ID: 14579716
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.